A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage.
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.
An autonomic disorder characterized by excessive sweating of the forehead, upper lip, perioral region, or sternum subsequent to gustatory stimuli. The auriculotemporal syndrome features facial flushing or sweating limited to the distribution of the auriculotemporal nerve and may develop after trauma to the parotid gland, in association with PAROTID NEOPLASMS, or following their surgical removal. (From Ann Neurol 1997 Dec;42(6):973-5)
Agents that improve the ability to carry out activities such as athletics, mental endurance, work, and resistance to stress. The substances can include PRESCRIPTION DRUGS; DIETARY SUPPLEMENTS; phytochemicals; and ILLICIT DRUGS.
The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.
An alkaloid, originally from Atropa belladonna, but found in other plants, mainly SOLANACEAE. Hyoscyamine is the 3(S)-endo isomer of atropine.
Drugs administered before an anesthetic to decrease a patient's anxiety and control the effects of that anesthetic.
Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants.
Cyclic GLUCANS consisting of eight (8) glucopyranose units linked by 1,4-glycosidic bonds.
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.
Analogs or derivatives of scopolamine.
Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.
The use of two or more chemicals simultaneously or sequentially to induce anesthesia. The drugs need not be in the same dosage form.
The tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.

Effects of anticholinergics on postoperative vomiting, recovery, and hospital stay in children undergoing tonsillectomy with or without adenoidectomy. (1/86)

BACKGROUND: Nausea and vomiting are the most frequent problems after minor ambulatory surgical procedures. The agents used to induce and maintain anesthesia may modify the incidence of emesis. When neuromuscular blockade is antagonized with anticholinesterases, atropine or glycopyrrolate is used commonly to prevent bradycardia and excessive oral secretions. This study was designed to evaluate the effect of atropine and glycopyrrolate on postoperative vomiting in children. METHODS: Ninety-three patients undergoing tonsillectomy with or without adenoidectomy were studied. After inhalation induction of anesthesia with nitrous oxide, oxygen, and halothane, anesthesia was maintained with a nitrous oxide-oxygen mixture, halothane, morphine, and atracurium. Patients were randomized to receive, in a double-blinded manner, either 15 microg/kg atropine or 10 microg/kg glycopyrrolate with 60 microg/kg neostigmine to reverse neuromuscular blockade. Patient recovery, the incidence of postoperative emesis, antiemetic therapy, and the duration of postoperative hospital stay were assessed. RESULTS: There were no significant differences in age, gender, weight, or discharge time from the postanesthesia care unit or the hospital between the groups. Twenty-four hours after operation, the incidence of vomiting in the atropine group (56%) was significantly less than in the glycopyrrolate group (81%; P<0.05). There was no significant difference between the atropine and glycopyrrolate groups in the number of patients who required antiemetics or additional analgesics. CONCLUSIONS: In children undergoing tonsillectomy with or without adenoidectomy, reversal of neuromuscular blockade with atropine and neostigmine is associated with a lesser incidence of postoperative emesis compared with glycopyrrolate and neostigmine.  (+info)

Neostigmine with glycopyrrolate does not increase the incidence or severity of postoperative nausea and vomiting in outpatients undergoing gynaecological laparoscopy. (2/86)

We studied 100 healthy women undergoing outpatient gynaecological laparoscopy in a randomized, double-blind and placebo-controlled study to evaluate the effect of neostigmine on postoperative nausea and vomiting (PONV). After induction of anaesthesia with propofol, anaesthesia was maintained with sevoflurane and 66% nitrous oxide in oxygen. Mivacurium was used for neuromuscular block. At the end of anaesthesia, neostigmine 2.0 mg and glycopyrrolate 0.4 mg, or saline, was given i.v. The incidence of PONV was evaluated in the postanaesthesia care unit, on the ward and at home. The severity of nausea and vomiting, worst pain, antiemetic and analgesic use, times to urinary voiding and home readiness were recorded. During the first 24 h after operation, 44% of patients in the neostigmine group and 43% in the saline group did not have PONV. We conclude that neostigmine with glycopyrrolate did not increase the occurrence of PONV in this patient group.  (+info)

Dose effect and benefits of glycopyrrolate in the treatment of bradycardia in anesthetized dogs. (3/86)

This study evaluated the effectiveness of glycopyrrolate (0.005 or 0.01 mg/kg body weight (BW)) in anesthetized dogs (n = 40) for reversal of bradycardia (< 65 beats/min). Following random intravenous (i.v.) treatment, heart rate was determined at 5 min and, if it was < or = 70 beats/min, the lower dose was repeated. A 2-way analysis of variance considered dose and animal size (< or = 10 kg, > 10 kg) effects (P < 0.05). Glycopyrrolate produced a significant increase in heart rate and infrequent tachycardia (< or = 150 beats/min), which was not dose-related. The size of the dog produced a significant effect on baseline heart rate (higher in small), rate following the first dose (lower in small), and requirement for retreatment (47% in small, 13% in large). In a separate group of anesthetized dogs (n = 20), the blood pressure effect of glycopyrrolate (0.01 mg/kg BW, i.v.) treatment of bradycardia (65-85 beats/min, weight-adjusted) was studied. A significant increase in systolic, diastolic, and mean blood pressure was produced. In conclusion, the effective dose of glycopyrrolate treatment is size-related and produces a beneficial effect on blood pressure.  (+info)

Glycopyrrolate reduces nausea during spinal anaesthesia for caesarean section without affecting neonatal outcome. (4/86)

We have tested the hypotheses that glycopyrrolate, administered immediately before induction of subarachnoid anaesthesia for elective Caesarean section, reduces the incidence and severity of nausea, with no adverse effects on neonatal Apgar scores, in a double-blind, randomized, controlled study. Fifty women received either glycopyrrolate 200 micrograms or saline (placebo) i.v. during fluid preload, before induction of spinal anaesthesia with 2.5 ml of 0.5% isobaric bupivacaine. Patients were questioned directly regarding nausea at 3-min intervals throughout operation and asked to report symptoms as they arose. The severity of nausea was assessed using a verbal scoring system and was treated with increments of i.v. ephedrine and fluids. Patients in the group pretreated with glycopyrrolate reported a reduction in the frequency (P = 0.02) and severity (P = 0.03) of nausea. Glycopyrrolate also reduced the severity of hypotension, as evidenced by reduced ephedrine requirements (P = 0.02). There were no differences in neonatal Apgar scores between groups.  (+info)

Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. (5/86)

1. In this study we have evaluated the pharmacological profile of the muscarinic antagonist glycopyrrolate in guinea-pig and human airways in comparison with the commonly used antagonist ipratropium bromide. 2. Glycopyrrolate and ipratropium bromide inhibited EFS-induced contraction of guinea-pig trachea and human airways in a concentration-dependent manner. Glycopyrrolate was more potent than ipratropium bromide. 3. The onset of action (time to attainment of 50% of maximum response) of glycopyrrolate was similar to that obtained with ipratropium bromide in both preparations. In guinea-pig trachea, the offset of action (time taken for response to return to 50% recovery after wash out of the test antagonist) for glycopyrrolate (t1/2 [offset]=26.4+/-0.5 min) was less than that obtained with ipratropium bromide (81.2+/-3.7 min). In human airways, however, the duration of action of glycopyrrolate (t1/2 [offset]>96 min) was significantly more prolonged compared to ipratropium bromide (t1/2 [offset]= 59.2+/-17.8 min). 4. In competition studies, glycopyrrolate and ipratropium bromide bind human peripheral lung and human airway smooth muscle (HASM) muscarinic receptors with affinities in the nanomolar range (K1 values 0.5-3.6 nM). Similar to ipratropium bromide, glycopyrrolate showed no selectivity in its binding to the M1-M3 receptors. Kinetics studies, however, showed that glycopyrrolate dissociates slowly from HASM muscarinic receptors (60% protection against [3H]-NMS binding at 30 nM) compared to ipratropium bromide. 5. These results suggest that glycopyrrolate bind human and guinea-pig airway muscarinic receptors with high affinity. Furthermore, we suggest that the slow dissociation profile of glycopyrrolate might be the underlying mechanism by which this drug accomplishes its long duration of action.  (+info)

Orthostatic hypotension in aging humans. (6/86)

We tested the hypothesis that hypotension occurred in older adults at the onset of orthostatic challenge as a result of vagal dysfunction. Responses of heart rate (HR) and mean arterial pressure (MAP) were compared between 10 healthy older and younger adults during onset and sustained lower body negative pressure (LBNP). A younger group was also assessed after blockade of the parasympathetic nervous system with the use of atropine or glycopyrrolate and after blockade of the beta(1)-adrenoceptor by use of metoprolol. Baseline HR (older vs. younger: 59 +/- 4 vs. 54 +/- 1 beats/min) and MAP (83 +/- 2 vs. 89 +/- 3 mmHg) were not significantly different between the groups. During -40 Torr, significant tachycardia occurred at the first HR response in the younger subjects without hypotension, whereas significant hypotension [change in MAP (DeltaMAP) -7 +/- 2 mmHg] was observed in the elderly without tachycardia. After the parasympathetic blockade, tachycardiac responses of younger subjects were diminished and associated with a significant hypotension at the onset of LBNP. However, MAP was not affected after the cardiac sympathetic blockade. We concluded that the elderly experienced orthostatic hypotension at the onset of orthostatic challenge because of a diminished HR response. However, an augmented vasoconstriction helped with the maintenance of their blood pressure during sustained LBNP.  (+info)

Effects of 8 h of isocapnic hypoxia with and without muscarinic blockade on ventilation and heart rate in humans. (7/86)

This study examined the role of muscarinic parasympathetic mechanisms in generating the progressive increases in ventilation (V(E)) and heart rate previously reported with 8 h exposures to hypoxia. The sensitivities of V(E) (G(p)) and heart rate (G(HR)) to acute variations in hypoxia, and V(E) and heart rate during acute hyperoxia were assessed in 10 subjects before and after two 8 h exposures to isocapnic hypoxia (end-tidal P(O2) = 50 mmHg). The responses were measured during muscarinic blockade with glycopyrrolate (0.015 mg kg(-1)) and without glycopyrrolate, as a control. There were significant increases in G(p) (P < 0.01) and V(E) during hyperoxia (P < 0.01) following hypoxic exposure, but these were unaffected by glycopyrrolate. G(HR) increased significantly by 0.29 +/- 0.08 beats min(-1) %(-1) (mean +/- S.E.M.) following exposure to hypoxia under control conditions, but only non-significantly by 0.10 +/- 0.08 beats min(-1) %(-1) with glycopyrrolate. This difference was significant. Changes in heart rate during hyperoxia were slight and inconclusive. We conclude that muscarinic mechanisms play little role in the progressive ventilatory changes that occur over 8 h of hypoxia, but that they do mediate much of the progressive increase in heart rate. Experimental Physiology (2001) 86.4, 529-538.  (+info)

Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. (8/86)

Nonviral vectors have been shown to be a safe and valid alternative to recombinant viruses for gene therapy of cystic fibrosis (CF). Nevertheless, gene transfer efficiency needs to be increased before clinical efficacy is likely in man. One barrier to increased efficacy is normal airway mucus. Using an ex vivo model of sheep tracheal epithelium, we show that this barrier can, in part, be overcome by treatment with the mucolytic agents, Nacystelyn or N-acetylcysteine using either a cationic lipid or a cationic polymer as the gene transfer agent. Further, in vivo application of either Nacystelyn or the anticholinergic glycopyrrolate, both clinically used agents, resulted in increased reporter gene expression in the mouse lung, but no significant correction of the bioelectric defect in CF null mice. These results, whilst unlikely to be sufficient in themselves to achieve clinically relevant gene therapy, may be a further useful step in the attainment of this goal.  (+info)

The medical term for gustatory sweat is gustatory hyperhidrosis. It can be caused by a variety of factors, including:

* Strong flavors: Certain strong-tasting foods and beverages, such as spicy or sour foods, can trigger excessive sweating in some people.
* Food allergies: Some people may experience gustatory sweat as an allergic response to certain foods or ingredients.
* Neurological disorders: Certain neurological conditions, such as Parkinson's disease or Multiple Sclerosis, can cause gustatory sweating as a symptom.
* Psychological factors: Strong emotional responses to food or drink, such as excitement or anxiety, can also trigger gustatory sweat.

Gustatory sweat is usually not a cause for concern and can be managed with simple lifestyle changes, such as avoiding trigger foods or beverages or using antiperspirants. However, if the condition persists or worsens over time, it is important to consult with a healthcare professional to rule out any underlying medical conditions.

* Heart block: A condition where the electrical signals that control the heart's rhythm are blocked or delayed, leading to a slow heart rate.
* Sinus node dysfunction: A condition where the sinus node, which is responsible for setting the heart's rhythm, is not functioning properly, leading to a slow heart rate.
* Medications: Certain medications, such as beta blockers, can slow down the heart rate.
* Heart failure: In severe cases of heart failure, the heart may become so weak that it cannot pump blood effectively, leading to a slow heart rate.
* Electrolyte imbalance: An imbalance of electrolytes, such as potassium or magnesium, can affect the heart's ability to function properly and cause a slow heart rate.
* Other medical conditions: Certain medical conditions, such as hypothyroidism (an underactive thyroid) or anemia, can cause bradycardia.

Bradycardia can cause symptoms such as:

* Fatigue
* Weakness
* Dizziness or lightheadedness
* Shortness of breath
* Chest pain or discomfort

In some cases, bradycardia may not cause any noticeable symptoms at all.

If you suspect you have bradycardia, it is important to consult with a healthcare professional for proper diagnosis and treatment. They may perform tests such as an electrocardiogram (ECG) or stress test to determine the cause of your slow heart rate and develop an appropriate treatment plan. Treatment options for bradycardia may include:

* Medications: Such as atropine or digoxin, to increase the heart rate.
* Pacemakers: A small device that is implanted in the chest to help regulate the heart's rhythm and increase the heart rate.
* Cardiac resynchronization therapy (CRT): A procedure that involves implanting a device that helps both ventricles of the heart beat together, improving the heart's pumping function.

It is important to note that bradycardia can be a symptom of an underlying condition, so it is important to address the underlying cause in order to effectively treat the bradycardia.

Gallanosa A, Stevens JB, Quick J (2021). "Glycopyrrolate". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID ...
"Robinul- glycopyrrolate tablet Robinul Forte- glycopyrrolate tablet". DailyMed. 1 June 2021. Retrieved 20 June 2022. "Dartisla ... Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M (December 2000). "Treatment of sialorrhea with glycopyrrolate: A ... Kim WO, Kil HK, Yoon KB, Yoon DM (May 2008). "Topical glycopyrrolate for patients with facial hyperhidrosis". Br. J. Dermatol. ... "Glycopyrrolate Oral Inhalation". MedlinePlus. Archived from the original on 17 August 2021. Retrieved 20 June 2022. " ...
Glycopyrrolate is another drug sometimes used. It is said to be nearly as effective as oxybutynin, but has similar side-effects ... Anticholinergics used for hyperhidrosis include propantheline, glycopyrronium bromide or glycopyrrolate, oxybutynin, ...
... toxicology and clinical safety of glycopyrrolate". Toxicology and Applied Pharmacology. 370: 154-169. doi:10.1016/j.taap. ...
To assist with vertigo and balance problems, glycopyrrolate has been found to be a useful vestibular suppressant in patients ... Storper, Ian S.; Spitzer, Jaclyn B.; Scanlan, Mark (1998). "Use of glycopyrrolate in the treatment of Meniere's disease". The ...
Gaboxadol Propantheline bromide Glycopyrrolate Oxybutynin World Health Organization (December 1959). "International Non- ...
One of the more effective treatments is oral or topically applied glycopyrrolate.[citation needed] James, William D.; Elston, ...
N-substituted soft anticholinergics based on glycopyrrolate". J. Pharm. Pharmacol. 57 (11): 1427-35. doi:10.1211/jpp.57.11.0008 ...
Bradycardia caused by xylazine administration is effectively prevented by administration of atropine or glycopyrrolate. ...
Therefore, glycopyrrolate, an anticholinergic drug, should be given immediately prior to neostigmine to prevent bradycardia. ...
For this reason it is usually given along with an anti-cholinergic drug such as atropine or glycopyrrolate.[medical citation ...
Other drugs used are glycopyrrolate and botulinum toxin A - botox injection in salivary glands to diminish saliva production. ...
... the tolerability profile of sugammadex was generally similar to that of placebo or neostigmine plus glycopyrrolate. Sugammadex ...
In very serious cases of hyperhidrosis, a solution containing glycopyrronium bromide or glycopyrrolate, a cholinergic inhibitor ...
If not, the use of atropine or glycopyrrolate will usually be successful and permit continuation of the surgical procedure. ... such as atropine or glycopyrrolate. If bradycardia does occur, removal of the stimulus is immediately indicated. This often ...
Atropine, scopolamine, amitriptyline or glycopyrrolate may be prescribed when people with ALS begin having trouble swallowing ...
... glycopyrrolate MeSH D03.383.773.371 - imino furanoses MeSH D03.383.773.400 - kainic acid MeSH D03.383.773.475 - lincomycin MeSH ...
... including botulinum toxin A and benztropine and glycopyrrolate. Bisphosphonates are used to treat osteoporosis in adults. ...
Treatment involves the application of an antiperspirant or glycopyrrolate to the cheek, Jacobsen's neurectomy along the middle ...
... glycopyrrolate) Monitors: electrocardiography, electroencephalography, electromyography, entropy monitoring, neuromuscular ...
... glycopyrrolate MeSH D02.092.877.435 - hemicholinium 3 MeSH D02.092.877.475 - lissamine green dyes MeSH D02.092.877.648 - ... glycopyrrolate MeSH D02.675.276.435 - hemicholinium 3 MeSH D02.675.276.475 - lissamine green dyes MeSH D02.675.276.534 - ...
... combination drug product used to treat ear disease in dogs glycopyrrolate - emergency drug used for cardiac support ...
Dimenhydrinate Diphenhydramine Doxepin Doxylamine Flavoxate Glycopyrrolate Glycopyrronium Hyoscyamine Ipratropium Orphenadrine ...
... glycopyrrolate. As of 2008, it is unclear if medication for people who have too much saliva due to clozapine treatment is ...
... DESCRIPTION. Glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a ... Glycopyrrolate Tablets 2 mg. The recommended dosage of glycopyrrolate for adults is one tablet two or three times daily at ... Glycopyrrolate Tablets 1 mg. The recommended initial dosage of glycopyrrolate for adults is one tablet three times daily (in ... Glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate. ...
Glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound ... Each 1 mg tablet contains: Glycopyrrolate, USP ................1 mg. Each 2 mg tablet contains: Glycopyrrolate, USP ... GLYCOPYRROLATE tablet. To receive this label RSS feed. Copy the URL below and paste it into your RSS Reader application. https ... GLYCOPYRROLATE tablet. If this SPL contains inactivated NDCs listed by the FDA initiated compliance action, they will be ...
Glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound ... Glycopyrrolate Tablets 2 mg. The recommended dosage of glycopyrrolate for adults is one tablet two or three times daily at ... Glycopyrrolate Tablets 1 mg. The recommended initial dosage of glycopyrrolate for adults is one tablet three times daily (in ... Glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate. ...
... glycopyrrolate) is a prescription inhaler used for long-term maintenance treatment of Chronic Obstructive Pulmonary Disease ( ... Generic drug: glycopyrrolate. Brand name: Seebri Neohaler. Seebri Neohaler is an anticholinergic medicine known as ... Seebri Neohaler is an anticholinergic medicine known as glycopyrrolate used for long-term maintenance treatment of Chronic ... glycopyrrolate.. *Anticholinergic medicines such as Seebri Neohaler help the muscles around the airways in your lungs stay ...
Glycopyrrolate: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking glycopyrrolate,. *tell your doctor and pharmacist if you are allergic to glycopyrrolate, any other medications, ... Take glycopyrrolate exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. ... Glycopyrrolate may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: *dry mouth ...
Learn about drug interactions between umeclidinium-vilanterol inhl and glycopyrrolate inj and use the RxList drug interaction ... Drug interactions with umeclidinium-vilanterol inhl and glycopyrrolate inj. home drug interactions checker , umeclidinium- ... All generic drug interactions for glycopyrrolate inj (lists will include brand and generic names): ...
Glycopyrrolate Glycopyrrolate is used in combination with other medications to treat ulcers in adults and children 12 years of ... Glycopyrrolate Oral Inhalation Bevespi Aerosphere®(as a combination product containing Glycopyrrolate, Formoterol)® ... Utibron ... olodaterol (Stiolto Respimat) Umeclidinium and vilanterol (Anoro Ellipta) Glycopyrrolate and formoterol (Bevespi Aerosphere) ...
Because glycopyrrolate is a quaternary ammonium compound, it is not likely to be absorbed and reach the bloodstream of the ... No information is available on the use of glycopyrrolate during breastfeeding. ... No information is available on the use of glycopyrrolate during breastfeeding. Because glycopyrrolate is a quaternary ammonium ... Nebulized glycopyrrolate (Lonhala Magnair) for COPD. [No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Apr 23; ...
Glycopyrrolate has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury. ... Glycopyrrolate is an anticholinergic agent used to treat gastrointestinal conditions associated with intestinal spasm and to ... Glycopyrrolate No authors listed In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. ... Glycopyrrolate is an anticholinergic agent used to treat gastrointestinal conditions associated with intestinal spasm and to ...
Because glycopyrrolate is a quaternary ammonium compound, it is not likely to be absorbed and reach the bloodstream of the ... infant, especially when given by inhalation or topically on the skin.[1-3] Long-term oral use of glycopyrrolate might reduce ... No information is available on the use of glycopyrrolate during breastfeeding. ... Nebulized glycopyrrolate (Lonhala Magnair) for COPD.[Med Lett Drugs Ther. 2018]. Nebulized glycopyrrolate (Lonhala Magnair) for ...
Active Comparator: : Glycopyrrolate Injection 50 mcg glycopyrrolate via IV infusion. Drug: Glycopyrrolate Injection 50 mcg ... 50 mcg glycopyrrolate via Electronic Nebulizer. Drug: SUN-101 via eFlow nebulizer 50 mcg glycopyrrolate via Electronic ... 50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal. Drug: SUN-101 via eFlow nebulizer with activated ... Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate [ Time Frame: Up to Week 5 ]. The time 0 is based ...
... glycopyrrolate), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation ... glycopyrrolate oral GLYCOPYRROLATE DISINTEGRATING TABLET - ORAL (GLYE-koe-PIR-oh-late) COMMON BRAND NAME(S): Dartisla USES: ... encoded search term (glycopyrrolate (Cuvposa%2C Dartisla ODT)) and glycopyrrolate (Cuvposa, Dartisla ODT) What to Read Next on ... Switching from other oral glycopyrrolate. *Patients receiving 2 mg of another oral tablet dosage form of glycopyrrolate may be ...
Glycopyrrolate by Drug Facts Glycopyrrolate by is a Prescription medication manufactured, distributed, or labeled by Medical ... Glycopyrrolate (glycopyrrolate) Injection, 0.2 mg/mL, is available as:. 0.2 mg/1 mL Single-dose Vials packaged in 25s (NDC ... Glycopyrrolate Injection is a clear, colorless, sterile liquid; pH 2.0 - 3.0. The partition coefficient of glycopyrrolate in a ... GLYCOPYRROLATE (UNII: V92SO9WP2I) (GLYCOPYRRONIUM - UNII:A14FB57V1D) GLYCOPYRROLATE. 0.2 mg in 1 mL. ...
Glycopyrrolate. Revision as of 17:14, 6 May 2022 by Masoodrm. (talk , contribs) (→‎Administration) ... Retrieved from "https://www.wikem.org/w/index.php?title=Glycopyrrolate&oldid=350499" ...
Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol. 2008 May. 158(5):1094-7. [QxMD MEDLINE Link]. ... Glycopyrrolate acts in the smooth muscle, CNS, and secretory glands to block the action of acetylcholine at parasympathetic ...
Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol. 2008 May. 158(5):1094-7. [QxMD MEDLINE Link]. ... Glycopyrrolate acts in the smooth muscle, CNS, and secretory glands to block the action of acetylcholine at parasympathetic ...
Find information on Glycopyrrolate (Systemic) - Cuvposa, Glyrx-PF in Daviss Drug Guide including dosage, side effects, ... "Glycopyrrolate (systemic)." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. Emergency Central, emergency. ... Glycopyrrolate (systemic) [Internet]. In: Daviss Drug Guide. F.A. Davis Company; 2023. [cited 2023 June 04]. Available from: ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Glycopyrrolate (systemic). In Daviss Drug Guide (18th ed.). F.A. Davis ...
Find information on Glycopyrrolate (Systemic) - Cuvposa, Glyrx-PF in Daviss Drug Guide including dosage, side effects, ... "Glycopyrrolate (systemic)." Daviss Drug Guide, 18th ed., F.A. Davis Company, 2023. Anesthesia Central, anesth.unboundmedicine. ... Glycopyrrolate (systemic) [Internet]. In: Daviss Drug Guide. F.A. Davis Company; 2023. [cited 2023 June 05]. Available from: ... Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Glycopyrrolate (systemic). In Daviss Drug Guide (18th ed.). F.A. Davis ...
... of Glycopyrrolate EP Impurity K having CAS No 3900-93-4, Synonyms: (2RS)-2-Cyclopentyl-2-phenylacetic acid, . C13H16O2, 204.26 ... Order Glycopyrrolate EP Impurity K product with CAS: 3900-93-4 and speed up your Glycopyrrolate project. This product is also ... Glycopyrrolate Impurities, Impurities Glycopyrrolate USP Releted Compound L CAS No.. : 19833-96-6. ... Glycopyrrolate Impurities, Impurities Glycopyrrolate EP Impurity O. CAS No.. : 618-88-2. ...
20180308-5D7767_Glycopyrrolate_0.2mg_per_mL_in_3mL-signed. Posted April 3, 2018. by Certificate Manager ...
Glycopyrrolate. 242,494. 1.7. 20,706,229. 2.8. Other. 4,114,833. 29.6. 65,854,357. 8.9. Total. 13,914,807. 100.0%. $743,481,166 ...
You should not use this medicine if you or your child are using the following medicines: arsenic trioxide (Trisenox®), cisapride (Propulsid®), dolasetron mesylate (Anzemet®), droperidol (Dridol®, Inapsine®), levomethadyl acetate (Orlaam®), methylphenidate (Ritalin®), pemoline (Cylert®), pentamidine (Nebupent®), probucol, tacrolimus (Prograf®), zileuton (Zyflo®), amphetamines (such as Desoxyn®, Dexedrine®), medicine for heart rhythm problems (such as amiodarone, disopyramide, dofetilide, procainamide, quinidine, sotalol, Betapace®, Cardioquin®, Cordarone®, Norpace®, Procanbid®, Quinaglute®, or Tikosyn®), medicine for depression (such as amitriptyline, citalopram, escitalopram, fluoxetine, fluvoxamine, nefazodone, nortriptyline, paroxetine, sertraline, Celexa®, Elavil®, Lexapro™, Luvox®, Pamelor®, Paxil®, Prozac®, Sarafem®, Serzone®, Vivactil®, or Zoloft®), certain antibiotics (such as azithromycin, clarithromycin, dirithromycin, erythromycin, gatifloxacin, ...
glycopyrrolate). oral solution. NDA 022571. July 28, 2010. For reducing chronic, severe drooling in patients who are 3 to 16 ...
Glycopyrrolate. For more information on this medication choose from the list of selections below. ...
Find information on Furosemide (Lasix) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
In conclusion, glycopyrrolate similarly protects large and small airways, whereas the protective effect of indacaterol in the ... In conclusion, glycopyrrolate similarly protects large and small airways, whereas the protective effect of indacaterol in the ... In conclusion, glycopyrrolate similarly protects large and small airways, whereas the protective effect of indacaterol in the ... In conclusion, glycopyrrolate similarly protects large and small airways, whereas the protective effect of indacaterol in the ...
Robinul (glycopyrrolate): a medication that decreases secretions, such as saliva. Because the medications can cause many ...
  • Glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. (nih.gov)
  • Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. (nih.gov)
  • Seebri Neohaler is an anticholinergic medicine known as glycopyrrolate . (medicinenet.com)
  • Glycopyrrolate is an anticholinergic agent used to treat gastrointestinal conditions associated with intestinal spasm and to decrease secretions during anesthesia. (nih.gov)
  • Bronchoprotection by indacaterol (β2-agonist) and glycopyrrolate (anticholinergic) against methacholine- and EFS-induced constrictions of large and small airways was measured in guinea pig and human lung slices using video-assisted microscopy. (rug.nl)
  • Glycopyrrolate (Cuvposa) is used to reduce saliva and drooling in children between 3 and16 years of age that have certain medical conditions that cause drooling. (medlineplus.gov)
  • glycopyrronium tosylate topical, glycopyrrolate. (medscape.com)
  • Because glycopyrrolate is a quaternary ammonium compound, it is not likely to be absorbed and reach the bloodstream of the infant, especially when given by inhalation or topically on the skin. (nih.gov)
  • Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. (nih.gov)
  • Prescription drugs such as meclizine, diazepam, glycopyrrolate, and lorazepam can help relieve dizziness and shorten the attack. (nih.gov)
  • Prior to anesthesia, glycopyrrolate (100 mg/kg SC) will be administered approximately 15 minutes prior to anesthesia. (nih.gov)
  • Indacaterol (10 μM) and glycopyrrolate (10 nM) normalized small airway hyperresponsiveness in COPD lung slices. (rug.nl)
  • Synergy of low indacaterol (10 nM) and glycopyrrolate (1 nM) concentrations was greater in LPS-challenged guinea pigs (COPD model) compared to saline-challenged controls. (rug.nl)
  • In conclusion, glycopyrrolate similarly protects large and small airways, whereas the protective effect of indacaterol in the small, but not the large, airways depends on the contractile stimulus used. (rug.nl)
  • Moreover, findings in a guinea pig model indicate that the synergistic bronchoprotective effect of indacaterol and glycopyrrolate is enhanced in COPD. (rug.nl)
  • Glycopyrrolate comes as a tablet and solution (liquid) to take by mouth. (medlineplus.gov)
  • glycopyrrolate, umeclidinium bromide/vilanterol inhaled. (medscape.com)
  • Glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate. (nih.gov)
  • tell your doctor and pharmacist if you are allergic to glycopyrrolate, any other medications, or any of the ingredients in glycopyrrolate tablets or solution. (medlineplus.gov)
  • Glycopyrrolate is in a class of medications called anticholinergics. (medlineplus.gov)
  • Anticholinergics and ketamine sedation in children: a secondary analysis of atropine versus glycopyrrolate. (nih.gov)
  • Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (clinicaltrials.gov)
  • 8. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. (nih.gov)
  • If you become pregnant while taking glycopyrrolate, call your doctor. (medlineplus.gov)
  • 1-3] Long-term oral use of glycopyrrolate might reduce milk production or milk letdown, but a single dose is unlikely to interfere with breastfeeding. (nih.gov)
  • concurrent use with oral glycopyrrolate solution contraindicated. (unboundmedicine.com)
  • Glycopyrrolate is used in combination with other medications to treat ulcers in adults and children 12 years of age and older. (medlineplus.gov)
  • Many other medications may also interact with glycopyrrolate, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. (medlineplus.gov)
  • Glycopyrrolate acts in the smooth muscle, CNS, and secretory glands to block the action of acetylcholine at parasympathetic sites. (medscape.com)
  • you should know that glycopyrrolate may make you drowsy or cause blurred vision. (medlineplus.gov)
  • Glycopyrrolate may produce drowsiness and blurred vision. (nih.gov)
  • Glycopyrrolate is an anticholinergic agent used to treat gastrointestinal conditions associated with intestinal spasm and to decrease secretions during anesthesia. (nih.gov)
  • Prior to anesthesia, glycopyrrolate (100 mg/kg SC) will be administered approximately 15 minutes prior to anesthesia. (nih.gov)
  • Glycopyrrolate injection, USP is a synthetic anticholinergic agent. (nih.gov)
  • Glycopyrrolate (glye" koe pir' oh late) is a synthetic quaternary ammonium anticholinergic agent which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing respiratory and gastrointestinal secretions and intestinal motility. (nih.gov)
  • Glycopyrrolate is also used to antagonize the peripheral muscarinic effects (bronchospasm, bradycardia, and increased gastrointestinal motility) produced by acetylcholinesterases such as neostigmine when they are given postoperatively to reverse non-depolarizing neuromuscular blocking agents. (medscape.com)
  • Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases. (nih.gov)
  • Glycopyrrolate has broad activity against muscarinic acetylcholine receptors, but its highly polar quaternary ammonium group makes it less likely to cross lipid membranes such as the blood brain barrier, which is believed to decrease the potential for central nervous system effects. (nih.gov)
  • Glycopyrrolate is available in tablets of 1 and 2 mg in several generic forms and under the brand name Robinul. (nih.gov)
  • Unlike atropine, glycopyrrolate is completely ionized at physiological pH values. (nih.gov)
  • Anticholinergics and ketamine sedation in children: a secondary analysis of atropine versus glycopyrrolate. (nih.gov)
  • After IV (Intravenous) administration of a 0.2 mg radiolabeled glycopyrrolate, 85% of dose recovered was recovered in urine 48 hours postdose and some of the radioactivity was also recovered in bile. (nih.gov)
  • In all, 31 children took at least one dose of oral glycopyrrolate. (nih.gov)
  • For many years, glycopyrrolate has been used off-label for the management of sialorrhea in children with cerebral palsy or other neurologic conditions and to reduce tracheobronchial secretions in children with tracheostomies. (medscape.com)
  • Gender differences in pharmacokinetics of glycopyrrolate have not been investigated. (nih.gov)
  • Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. (nih.gov)
  • Glycopyrrolate acts in the smooth muscle, CNS, and secretory glands to block the action of acetylcholine at parasympathetic sites. (medscape.com)
  • The mean age of hyperhidrosis onset was 10.3 years, and mean age of initiation of glycopyrrolate was 14.8 years. (nih.gov)
  • Glycopyrrolate (Cuvposa) is used to reduce saliva and drooling in children between 3 and16 years of age that have certain medical conditions that cause drooling. (medlineplus.gov)
  • The efficacy and adverse effects of oral glycopyrrolate were assessed. (nih.gov)
  • Glycopyrrolate, a synthetic anti-cholinergic, was approved for use by the Food and Drug Administration (FDA) in 1961. (medscape.com)
  • [ 3 ] On July 29, 2010, a new glycopyrrolate oral solution was approved by the FDA for the treatment of chronic severe sialorrhea caused by neurologic conditions in pediatric patients between 3 and 16 years of age. (medscape.com)
  • [ 4 ] This issue of Pediatric Pharmacotherapy will provide a brief review of the pharmacology of glycopyrrolate and an overview of recent case reports and studies related to its use in children. (medscape.com)
  • We sought to evaluate the response to oral glycopyrrolate in pediatric patients. (nih.gov)
  • Glycopyrrolate has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury. (nih.gov)
  • Like other anticholinergic agents, glycopyrrolate has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. (nih.gov)
  • Glycopyrrolate is used in combination with other medications to treat ulcers in adults and children 12 years of age and older. (medlineplus.gov)
  • After IM (Intramuscular) administration of glycopyrrolate to adults, the mean T1/2 value is reported to be between 0.55 to 1.25 hrs. (nih.gov)
  • Cite this: Glycopyrrolate Use in Children - Medscape - Dec 01, 2010. (medscape.com)
  • Following IV (Intravenous) administration (5 mcg/kg glycopyrrolate) to infants and children, the mean T1/2 values were reported to be between 21.6 and 130.0 minutes and between 19.2 and 99.2 minutes, respectively. (nih.gov)
  • Glycopyrrolate comes as a tablet and solution (liquid) to take by mouth. (medlineplus.gov)
  • These results suggest that the elimination of glycopyrrolate is severely impaired in patients with renal failure. (nih.gov)
  • Glycopyrrolate was approved for use in the United States in 1961 but is now not commonly used for gastrointestinal conditions, having been replaced by more effective antiulcer agents. (nih.gov)
  • Glycopyrrolate has been used largely for gastrointestinal conditions including peptic ulcer disease, gastrointestinal spasm and irritable colon. (nih.gov)